Description du projet
Un nouveau vaccin préserve la santé et la productivité du bétail
La vaccination constitue la stratégie la plus efficace pour protéger le bétail contre diverses maladies, en réduisant au minimum le recours aux antibiotiques. La diarrhée virale bovine (DVB) est une maladie endémique du bétail causée par le virus de la DVB (VDVB). Actuellement, aucun programme d’éradication ou de contrôle n’est mis en place, permettant d’éliminer le recours aux vaccins. Le projet BoVLP-BVD, financé par l’UE, a mis au point un vaccin innovant contre le VDVB, qui est basé sur une technologie brevetée de pseudoparticule virale. Les scientifiques entreprendront les actions nécessaires à la fabrication à l’échelle commerciale et à l’évaluation de l’innocuité et de l’efficacité in vivo du vaccin. Comme le VDVB nuit considérablement à la productivité et à la reproduction des troupeaux, en impliquant des coûts économiques importants, le vaccin BoVLP-BVD contribuera à la prévention de la maladie.
Objectif
In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime. Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals.
Aquilón CyL, a leading biotech company, has developed new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. Aquilón has demonstrated the technical, commercial and regulatory feasibility by the SME instrument phase 1 project (nº 774994). After developing the vaccine to TRL6 stage (pre-industrial prototype with positive activity data), Aquilón will develop one vaccine to TRL8 stage, demonstrating the commercial-scale manufacturing and in-vivo safety, efficacy and DIVA attributes in the target species. This vaccine candidate will be licensed to one or more veterinarian pharmaceutical company that will complete the final field studies required for commercialisation. Our business projections, based on agreements with Development milestones and commercial royalties, show potential for a 5X investment multiplier with a 25% internal rate of return.
Champ scientifique
- natural sciencesbiological sciencesmicrobiologyvirology
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- agricultural sciencesanimal and dairy sciencedomestic animalsanimal husbandry
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
24000 LEON
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.